Clinical trial
A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics, and Initial Efficacy of Single and Multiple Dosing of Peguricase for Injection With Methotrexate in Patients With Gout.
NCT06298071 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics, and Initial Efficacy of Single and Multiple Dosing of Peguricase for Injection With Methotrexate in Patients With Gout.
- Lead sponsor
- Shanghai Institute Of Biological Products
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 3, 2023
- Completion date
- December 30, 2026
- Enrollment
- 36 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.